Información del artículo
Bibliografía
Estadísticas
Bibliografía
[1]
National Cholesterol Education Program..
Second Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)..
Circulation, 89 (1994), pp. 1329-1445
[2]
Sociedad Española de Arteriosclerosi.s, Sociedad Española de Medicina Intern.a, Liga Española de la Lucha contra la Hipertensión Arterial..
Recomendaciones para la prevención primaria de la enfermedad cardiovascular..
Clin Invest Arteriosclerosis, 6 (1994), pp. 62-102
[3]
Informe SESPAS 1993: La salud y el sistema sanitario en España. Barcelona: S.G. Editores, S.A., 1993.
[4]
Verschuren M, Jacobs D, Bloemberg B, Kromhout D, Menotti A, Aravanis C et al..
Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five year follow-up of the Seven Countries Study..
JAMA, 274 (1995), pp. 131-136
[5]
Brotons C, Maiques A..
¿Debe administrarse terapia farmacológica hipolipemiante en normolipémicos o hiperlipémicos leves con factores de riesgo coronario? Argumentos en contra..
Rev Esp Cardiol, 49 (1996), pp. 486-491
[6]
Evaluación 1995 del Programa de Actividades Preventivas y de Promoción de la Salud. Barcelona, 1996.
[7]
Grover S, Lowensteyn I, Esrey K, Steinert Y, Joseph L, Abrahamowicz M..
Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study..
BMJ, 310 (1995), pp. 975-978
[9]
Shaper A, Pocock S, Philips A, Walker M..
Identifying men at high risk of heart attacks: strategy for use in general practice..
BMJ, 293 (1986), pp. 474-479
[10]
Anderson K, Wilson P, Odell P, Kannel W..
An updated coronary risk profile..
Circulation, 83 (1991), pp. 356-362
[11]
Evolución de la prescripción de hipolipemiantes en Cataluña (1991-1993). XIV Congreso de la Sociedad Española de Medicina Familiar y Comunitaria. Madrid, 1994.
[12]
Tunstall-Pedoe H..
The Dundee coronary risk-disk for management of change in risk factors..
BMJ, 303 (1991), pp. 744-747
[13]
Córdoba R, Lou S, Jimeno A, Sanz C..
Validación de un método de cálculo del riesgo cardiovascular en atención primaria..
Aten Primaria, 12 (1993), pp. 646-652
[14]
Haq I, Jackson P, Yeo W, Ramsay L..
Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart study..
Lancet, 346 (1995), pp. 1467-1471
[15]
Ramsay L, Haq I, Jackson P, Yeo W, Pickin D, Payne J..
Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table..
Lancet, 348 (1996), pp. 387-388
[16]
Ministerio de Sanidad y Consumo. Dirección General de Planificación Sanitaria. Madrid, mayo, 1989.
[17]
Diabetes care and research in Europe. The Saint Vincent Declaration Action Programme. Ginebra: WHO Regional Office for Europe, 1992.
[18]
Maiques A, Morales M, Franch M, Alfonso M, Moreno-Manzanaro P, García J..
Cálculo del riesgo coronario de los pacientes incluidos en el Programa de Actividades Preventivas y de Promoción de la Salud..
Aten Primaria, 15 (1995), pp. 86-92
[19]
López I, Montiel M, López A..
Empleo de una ecuación multifactorial para el cálculo de riesgo cardiovascular en una población rural de Lugo..
Clin Invest Arteriosclerosis, 7 (1995), pp. 99-102
[20]
Scandinavian Simvastatin Survival Study Group..
Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)..
Lancet, 344 (1994), pp. 1383-1389
[21]
Thompson G, Hollyer J, Waters D..
Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease..
Curr Opin Lipidol, 6 (1995), pp. 386-388
[22]
Gould AL, Rossouw J, Santanello N, Heyse J, Furberg C..
Cholesterol reduction yields clinical benefit. A new llok at old data..
Circulation, 91 (1995), pp. 2274-2282
[23]
Holme I..
Effects of lipid-lowering therapy on total and coronary mortality..
Curr Opin Lipidol, 6 (1995), pp. 374-378
[24]
Sacks F, Pfeffer M, Moye L, Rouleau J, Rutherford J, Cole T et al..
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels..
N Engl J Med, 335 (1996), pp. 1001-1009
[25]
Shepherd J, Cobbe S, Ford I, Isles C, Ross A, Macfarlane P et al..
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia..
N Engl J Med, 333 (1995), pp. 1301-1307
[26]
Pyorala K, De Backer G, Graham I, Poole-Wilson P, Wood D on behalf of the Task Force..
Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension..
Eur Heart J, 15 (1994), pp. 1300-1331
[27]
Guía de Prevención Cardiovascular. Madrid: Sociedad Española de Medicina Familiar y Comunitaria, 1996.
